Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation

• 資料種別: 記事
• タイトル: Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation
• 著者標目: Ohmoto Akihiro; Fuji Shigeo; Miyagi-Maeshima Akiko; Tajima Kinuko; Tanaka Takashi; Ito Reiko; Inoue Yoshitaka; Okinaka Keiji; Kurosawa Saiko; Inamoto Yoshihiro; Yamashita Takuya; Taniguchi Hirokazu; Makita Shinichi; Kitahara Hideaki; Munakata Wataru; Suzuki Tatsuya; Maruyama Dai; Kobayashi Yukio; Tanosaki Ryuji; Tobinai Kensei; Fukuda Takahiro; Kim Sung-Won
• 出版年月日等: 2016
• 出版年（W3CDTF）: 2016
• タイトル（掲載誌）: 日本造血細胞移植学会雑誌
• 巻号年月日等（掲載誌）: 5 3
• 掲載巻: 5
• 掲載号: 3
• 掲載ページ: 93-101
• 掲載年月日（W3CDTF）: 2016
• ISSN-L（掲載誌）: 21865612
• 出版事項（掲載誌）: Japanese Society for Transplantation and Cellular Therapy
• 本文の言語コード: en
• 件名標目: diffuse large B-cell lymphoma; autologous stem-cell transplantation; age-adjusted International Prognostic Index; Hans algorithm; rituximab
• 対象利用者: 一般
• DOI: 10.7889/hct.5.93; https://doi.org/10.7889/hct.5.93
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（URI）: https://www.jstage.jst.go.jp/article/hct/5/3/5_93/_pdf; https://search.jamas.or.jp/link/ui/2017253746
• 参照: Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma; https://cir.nii.ac.jp/crid/1360004231519780096; Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray; https://cir.nii.ac.jp/crid/1360011145121125376; Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation; https://cir.nii.ac.jp/crid/1360011145130607488; A quantitative study of peripheral blood stem cell contamination in diffuse large‐cell non‐Hodgkin's lymphoma: one‐half of patients significantly mobilize malignant cells; https://cir.nii.ac.jp/crid/1360011145767406336; Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma; https://cir.nii.ac.jp/crid/1360292620022237312; Germinal center B (GCB) and non‐GCB cell‐like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation; https://cir.nii.ac.jp/crid/1360574095966480512; The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP; https://cir.nii.ac.jp/crid/1360855569026002432; Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.; https://cir.nii.ac.jp/crid/1360855569798049408; A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR; https://cir.nii.ac.jp/crid/1360855569893721088; Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study; https://cir.nii.ac.jp/crid/1360855571283533312; Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma; https://cir.nii.ac.jp/crid/1361137044853985280; The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups; https://cir.nii.ac.jp/crid/1361137045667836160; Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients; https://cir.nii.ac.jp/crid/1361981468621456896; Pathogenesis of Non-Hodgkin's Lymphoma; https://cir.nii.ac.jp/crid/1362262943788757760; Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma; https://cir.nii.ac.jp/crid/1362262945608430848; Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma; https://cir.nii.ac.jp/crid/1362544419378430720; Impact of prior rituximab on outcomes of autologous stem‐cell transplantation in patients with relapsed or refractory aggressive B‐cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study; https://cir.nii.ac.jp/crid/1362544420820441472; MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program; https://cir.nii.ac.jp/crid/1362825893835744896; Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics; https://cir.nii.ac.jp/crid/1362825895236923136; Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma; https://cir.nii.ac.jp/crid/1363107368531988352; Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era; https://cir.nii.ac.jp/crid/1363107371079614208; CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group; https://cir.nii.ac.jp/crid/1363670318438078080; Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone; https://cir.nii.ac.jp/crid/1363670320988705536; The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in Second Complete or Partial Remission; https://cir.nii.ac.jp/crid/1364233268418606208; High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma; https://cir.nii.ac.jp/crid/1364233268929491200; High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells; https://cir.nii.ac.jp/crid/1364233269313727232; Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?; https://cir.nii.ac.jp/crid/1364233269500743168
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org; CiNii Articles
• NII論文ID: 130005165314

• 要約等: It is still unclear what factors are associated with a poor prognosis after ASCT for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The...